Search research articles
Contact Us
Filters
Showing results (11-20 of 41) with videos related to
Page
of 5
Sort By:
Nature
|
May 13, 2008
PML targeting eradicates quiescent leukaemia-initiating cells
Keisuke Ito, Rosa Bernardi, Alessandro Morotti, et al.
Experimental Hematology
|
February 12, 2008
Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival
Angela Shaulov, Simon Yue, Ruojie Wang, et al.
F1000Research
|
February 3, 2016
Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation
Eva Guinan, David E Avigan, Robert J Soiffer, et al.
Blood Cancer Journal
|
May 29, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Benjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, et al.
British Journal of Haematology
|
April 3, 2019
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013
Vincent Ribrag, David E Avigan, Damian J Green, et al.
Nature Medicine
|
August 21, 2012
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
Keisuke Ito, Arkaitz Carracedo, Dror Weiss, et al.
Transfusion
|
May 1, 2024
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality
Zachary M Avigan, Ajoy L Dias, Laura E Dodge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 13, 2023
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop
Evangelos Terpos, Paola Neri, Niels W C J van de Donk, et al.
Cell Stem Cell
|
July 6, 2013
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation
Su Jung Song, Keisuke Ito, Ugo Ala, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 26, 2007
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
David E Avigan, Baldev Vasir, Daniel J George, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 41) with videos related to
Sort By:
Page
of 5
Nature
|
May 13, 2008
PML targeting eradicates quiescent leukaemia-initiating cells
Keisuke Ito, Rosa Bernardi, Alessandro Morotti, et al.
Experimental Hematology
|
February 12, 2008
Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: implications for posttransplant survival
Angela Shaulov, Simon Yue, Ruojie Wang, et al.
F1000Research
|
February 3, 2016
Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation
Eva Guinan, David E Avigan, Robert J Soiffer, et al.
Blood Cancer Journal
|
May 29, 2024
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
Benjamin A Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, et al.
British Journal of Haematology
|
April 3, 2019
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013
Vincent Ribrag, David E Avigan, Damian J Green, et al.
Nature Medicine
|
August 21, 2012
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
Keisuke Ito, Arkaitz Carracedo, Dror Weiss, et al.
Transfusion
|
May 1, 2024
High CD34-positive cell dose in matched unrelated donor allogeneic hematopoietic stem cell transplant is not associated with graft-versus-host disease or mortality
Zachary M Avigan, Ajoy L Dias, Laura E Dodge, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 13, 2023
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop
Evangelos Terpos, Paola Neri, Niels W C J van de Donk, et al.
Cell Stem Cell
|
July 6, 2013
The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation
Su Jung Song, Keisuke Ito, Ugo Ala, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
September 26, 2007
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
David E Avigan, Baldev Vasir, Daniel J George, et al.
Page
of 5